Under this premise, different types of LYTACs have proven efficient EGFR degradation in epithelial ovarian cancer and HCC cell lines using cetuximab, an EGFR-blocking antibody, as the POI ligand and conjugating it with M6Pn [69]. This evidence concerns the gene EGFR and hepatocellular carcinoma.